After CTI BioPharma announced that a Phase 3 study of pixantrone in B-cell non-Hodgkin lymphoma failed to meet its primary endpoint, JMP Securities analyst Konstantinos Aprilakis said that his projections for the drug in that indication in the EU were modest and removing it from his model did not change his $8 price target on the stock. Pacritinib and the "tremendous opportunity" for it in myelofibrosis have always been central to his investment thesis for CTI, added Aprilakis, who maintains an Outperform rating on the stock, which fell 14% to close at $4.48 on Monday.